All In Biotech

Drug Trial Radar · NCT01216072

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Forms of Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC)

Last checked: Nov 20, 2026Latest source record: Feb 10, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,053 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,053

Actual

Start

Aug 2010

Primary completion

Aug 2012

Study completion Aug 2012

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 7, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the change in patient-reported outcomes, physician assessment of a change as well as safety and tolerability in patients with Relapsing Forms of Multiple Sclerosis on previous Disease Modifying Therapy (DMT) who are randomized to one of two treatment arms: fingolimod vs. standard of care DMT.

Conditions

  • Relapsing Forms of Multiple Sclerosis

Interventions

  • FingolimodDrug

    0.5 mg/day oral capsule

  • Standard MS DMTsDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Global Satisfaction Subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM) at Month 6Time frame: Baseline, Month 6

Locations

149 sites in 3 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Cullman, Alabama

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Tucson, Arizona

  • Novartis Investigative Site

    Anaheim, California

  • Novartis Investigative Site

    Berkeley, California

  • Novartis Investigative Site

    Fresno, California

  • Novartis Investigative Site

    Fullerton, California

  • Novartis Investigative Site

    La Habra, California

  • Novartis Investigative Site

    Loma Linda, California

  • Novartis Investigative Site

    Newport Beach, California

  • Novartis Investigative Site

    Oceanside, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    Walnut Creek, California

  • Novartis Investigative Site

    Boulder, Colorado

  • Novartis Investigative Site

    Colorado Springs, Colorado

  • Novartis Investigative Site

    Fort Collins, Colorado

  • Novartis Investigative Site

    Fairfield, Connecticut

  • Novartis Investigative Site

    New London, Connecticut

  • Novartis Investigative Site

    Stratford, Connecticut

  • Novartis Investigative Site

    Dover, Delaware

  • Novartis Investigative Site

    Newark, Delaware

  • Novartis Investigative Site

    Atlantis, Florida

  • Novartis Investigative Site

    Bradenton, Florida

  • Novartis Investigative Site

    Doral, Florida

  • Novartis Investigative Site

    Fort Lauderdale, Florida

  • Novartis Investigative Site

    Hollywood, Florida

  • Novartis Investigative Site

    Jacksonville, Florida

  • Novartis Investigative Site

    Jacksonville, Florida

  • Novartis Investigative Site

    Lighthouse PT, Florida

  • Novartis Investigative Site

    Maitland, Florida

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Pompano Beach, Florida

  • Novartis Investigative Site

    Ponte Vedra Beach, Florida

  • Novartis Investigative Site

    Port Orange, Florida

  • Novartis Investigative Site

    Sarasota, Florida

Showing 40 of 149 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.